Sort by

Send to

Choose Destination

Search results

Items: 17


Growth differentiating factor-15 (GDF-15): A potential biomarker and therapeutic target for cancer-associated weight loss.

Lerner L, Gyuris J, Nicoletti R, Gifford J, Krieger B, Jatoi A.

Oncol Lett. 2016 Nov;12(5):4219-4223.


Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients.

Lerner L, Hayes TG, Tao N, Krieger B, Feng B, Wu Z, Nicoletti R, Chiu MI, Gyuris J, Garcia JM.

J Cachexia Sarcopenia Muscle. 2015 Dec;6(4):317-24. doi: 10.1002/jcsm.12033.


23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity.

Proia T, Jiang F, Bell A, Nicoletti R, Kong L, Kreuter K, Poling L, Winston WM, Flaherty M, Weiler S, Perino S, O'Hagan R, Lin J, Gyuris J, Okamura H.

Mol Cancer Ther. 2015 Aug;14(8):1858-67. doi: 10.1158/1535-7163.MCT-14-1104.


Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor models.

Meetze K, Vincent S, Tyler S, Mazsa EK, Delpero AR, Bottega S, McIntosh D, Nicoletti R, Winston WM, Weiler S, Feng B, Gyuris J, Weng Z.

Clin Cancer Res. 2015 Mar 1;21(5):1106-14. doi: 10.1158/1078-0432.CCR-14-2407.


Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs.

Pennacchietti S, Cazzanti M, Bertotti A, Rideout WM 3rd, Han M, Gyuris J, Perera T, Comoglio PM, Trusolino L, Michieli P.

Cancer Res. 2014 Nov 15;74(22):6598-609. doi: 10.1158/0008-5472.CAN-14-0761.


Spontaneous genomic alterations in a chimeric model of colorectal cancer enable metastasis and guide effective combinatorial therapy.

Zhou Y, Rideout WM 3rd, Bressel A, Yalavarthi S, Zi T, Potz D, Farlow S, Brodeur J, Monti A, Reddipalli S, Xiao Q, Bottega S, Feng B, Chiu MI, Bosenberg M, Heyer J.

PLoS One. 2014 Aug 27;9(8):e105886. doi: 10.1371/journal.pone.0105886.


Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma.

Patnaik A, Weiss GJ, Papadopoulos KP, Hofmeister CC, Tibes R, Tolcher A, Isaacs R, Jac J, Han M, Payumo FC, Cotreau MM, Ramanathan RK.

Br J Cancer. 2014 Jul 15;111(2):272-80. doi: 10.1038/bjc.2014.290.


Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.

Gandhi L, Bahleda R, Tolaney SM, Kwak EL, Cleary JM, Pandya SS, Hollebecque A, Abbas R, Ananthakrishnan R, Berkenblit A, Krygowski M, Liang Y, Turnbull KW, Shapiro GI, Soria JC.

J Clin Oncol. 2014 Jan 10;32(2):68-75. doi: 10.1200/JCO.2012.47.2787.


Preclinical efficacy of the anti-hepatocyte growth factor antibody ficlatuzumab in a mouse brain orthotopic glioma model evaluated by bioluminescence, PET, and MRI.

Mittra ES, Fan-Minogue H, Lin FI, Karamchandani J, Sriram V, Han M, Gambhir SS.

Clin Cancer Res. 2013 Oct 15;19(20):5711-21. doi: 10.1158/1078-0432.CCR-12-1015.


Absorption, Metabolism, and Excretion of [(14) C]-Tivozanib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Male Participants: A Phase I, Open-Label, Mass-Balance Study.

Cotreau MM, Hale CL, Jacobson L, Oelke CS, Strahs AL, Kochan RG, Sanga M, Slichenmyer W, Vargo DL.

Clin Pharmacol Drug Dev. 2012 Jul;1(3):102-9. doi: 10.1177/2160763X12447303.


KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations.

O'Hagan RC, Heyer J.

Genes Cancer. 2011 Mar;2(3):335-43. doi: 10.1177/1947601911408080.


Development of second-generation VEGFR tyrosine kinase inhibitors: current status.

Bhargava P, Robinson MO.

Curr Oncol Rep. 2011 Apr;13(2):103-11. doi: 10.1007/s11912-011-0154-3. Review.


GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling.

Bai A, Meetze K, Vo NY, Kollipara S, Mazsa EK, Winston WM, Weiler S, Poling LL, Chen T, Ismail NS, Jiang J, Lerner L, Gyuris J, Weng Z.

Cancer Res. 2010 Oct 1;70(19):7630-9. doi: 10.1158/0008-5472.CAN-10-1489.


Non-germline genetically engineered mouse models for translational cancer research.

Heyer J, Kwong LN, Lowe SW, Chin L.

Nat Rev Cancer. 2010 Jul;10(7):470-80. doi: 10.1038/nrc2877. Review.


Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas.

Zhou Y, Rideout WM 3rd, Zi T, Bressel A, Reddypalli S, Rancourt R, Woo JK, Horner JW, Chin L, Chiu MI, Bosenberg M, Jacks T, Clark SC, Depinho RA, Robinson MO, Heyer J.

Nat Biotechnol. 2010 Jan;28(1):71-8. doi: 10.1038/nbt.1595.


VEGF kinase inhibitors: how do they cause hypertension?

Bhargava P.

Am J Physiol Regul Integr Comp Physiol. 2009 Jul;297(1):R1-5. doi: 10.1152/ajpregu.90502.2008. Review.


Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice.

Wu M, Jung L, Cooper AB, Fleet C, Chen L, Breault L, Clark K, Cai Z, Vincent S, Bottega S, Shen Q, Richardson A, Bosenburg M, Naber SP, DePinho RA, Kuperwasser C, Robinson MO.

Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7022-7. doi: 10.1073/pnas.0811785106.

Items per page

Supplemental Content

Loading ...
Support Center